Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease

2005 ◽  
Vol 11 (8) ◽  
pp. 895-900 ◽  
Author(s):  
Raymond M. Planinsic ◽  
Jan van der Meer ◽  
Giuliano Testa ◽  
Luis Grande ◽  
Angel Candela ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Chronic Liver ◽  
Bolus Administration ◽  
Safety And Efficacy ◽  
Single Bolus

Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients

2021 ◽  
Author(s):  
Mussarat N. Rahim ◽  
Eleni Theocharidou ◽  
Katherine Gar Yen Lau ◽  
Refah Ahmed ◽  
Flevin Marattukalam ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
In Vitro Fertilisation ◽  
Safety And Efficacy

Hepatic encephalopathy

2020 ◽  
pp. 3080-3089
Author(s):  
Paul K. Middleton ◽  
Debbie L. Shawcross
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Hepatic Encephalopathy ◽  
Chronic Liver Disease ◽  
Wide Spectrum ◽  
Chronic Liver ◽  
Electrolyte Disorders ◽  
The West ◽  
Optimal Medical Management ◽  
Type C

Hepatic encephalopathy (HE) is a significant complication of both acute and chronic liver disease, causing much morbidity and mortality. It is a complex neuropsychological condition, associated with hyperammonaemia and systemic inflammation, with a wide spectrum of symptoms. The West Haven criteria describe grades of severity from 0 (subclinical) and I (changes in awareness, mood, attention, cognition, and sleep pattern) through to IV (coma). It is further classified by the underlying aetiology: type A, due to acute liver failure; type B, secondary to portosystemic shunting; and type C, occurring in chronic liver disease in association with precipitating factors including infections, gastrointestinal bleeding, and electrolyte disorders, particularly hyponatraemia. There is no definitive test or set of diagnostic criteria to establish a diagnosis of HE, which remains primarily a clinical diagnosis of exclusion in patients with a history or clinical evidence of liver disease. Management depends on the type of HE, but for type C (the commonest type) typically includes lactulose and rifaximin. Patients with cirrhosis with ongoing overt HE despite optimal medical management have a dismal outlook and should be considered promptly for liver transplantation.

Portal Angiogenesis in Chronic Liver Disease Patients Correlates with Portal Pressure and Collateral Formation

2019 ◽  
Vol 37 (6) ◽  
pp. 498-508 ◽  
Author(s):  
Carolina A. Serrano ◽  
Simon C. Ling ◽  
Sofia Verdaguer ◽  
Miguel León ◽  
Nicolás Jarufe ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Portal Hypertension ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Venous Pressure ◽  
Portal Pressure ◽  
Peripheral Circulation ◽  
Chronic Liver ◽  
Noninvasive Markers ◽  
Collateral Formation

Background/Aims: One hallmark of chronic liver disease in patients with portal hypertension is the formation of portal-systemic collaterals in which angiogenesis has a fundamental role. We studied patients with chronic liver disease undergoing liver transplantation to correlate levels of circulating angiogenic factors in portal and peripheral circulation with portal pressure and portal-systemic collaterals. Methods: Sixteen patients who underwent liver transplantation were enrolled. During transplant surgery, we determined portal venous pressure and portal-systemic collateral formation. We determined angiogenics mediator levels in systemic and portal plasma. Peripheral plasma from healthy donors was measured as controls. Results: Vascular endothelial growth factor (VEGF)-R1 and 2, Ang-1 and 2, Tie2, FGF- 1 and 2, CD163, PDGFR-β, PDGFsRα, PDGF-AB and BB, CD163, TGF-β VASH-1 levels were significantly different in the controls in comparison to cases. Significantly decreased portal venous levels of Ang-1, FGF-1, PDGF-AB/BB, and CC were observed in patients with higher portal pressure. Peripheral VEGF, Ang-1, pPDGF-AB, BB, and CC were significantly decreased in patients with more severe collateral formation. While peripheral VEGF-R1 was higher in patients with severe collateral formation. For portal circulation, VEGF, Ang-1, ­pPDGF-AB, BB, and CC were significantly decreased in patients with more severe collateral formation Conclusions: Angiogenesis factors correlated with portal pressure and collateral formation and different patterns of circulating angiogenesis mediators were found in peripheral and portal blood of patients with chronic liver disease. These results support the importance of angiogenic pathways in cirrhosis and portal hypertension and highlight areas for further study to identify clinically useful noninvasive markers of portal pressure and collateral formation.

Bone Disorders in Patients With Chronic Liver Disease Awaiting Liver Transplantation

2010 ◽  
Vol 42 (4) ◽  
pp. 1191-1193 ◽  
Author(s):  
I. Loria ◽  
C. Albanese ◽  
M. Giusto ◽  
P.A. Galtieri ◽  
V. Giannelli ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Bone Disorders

scholarly journals Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation

2003 ◽  
Vol 77 (5) ◽  
pp. 1269-1277 ◽  
Author(s):  
Anja Bosy-Westphal ◽  
Martina Ruschmeyer ◽  
Norbert Czech ◽  
Gerd Oehler ◽  
Holger Hinrichsen ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Orthotopic Liver Transplantation ◽  
Chronic Liver

Vaccination against Hepatitis B in Patients with Chronic Liver Disease Awaiting Liver Transplantation

1999 ◽  
Vol 318 (5) ◽  
pp. 304-307 ◽  
Author(s):  
John C. Horlander ◽  
Nancy Boyle ◽  
Rajesh Manam ◽  
Melinda Schenk ◽  
Scott Herring ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Chronic Liver
Sign in / Sign up

Export Citation Format

Share Document